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Model of Spontaneous Lupus
Jessica L. Doerner1, Jing Wen1, Yumin Xia1, Karin Blecher Paz2, David Schairer2, Lan Wu3,
Samantha A. Chalmers1, Peter Izmirly4, Jennifer S. Michaelson5, Linda C. Burkly3, Adam J. Friedman2,7 and
Chaim Putterman1,6,7
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK, TNFSF12) and its sole receptor Fn14,
belonging to the TNF ligand and receptor superfamilies respectively, are involved in cell survival and cytokine
production. The role of TWEAK/Fn14 interactions in the pathogenesis of cutaneous lupus has not been explored.
TWEAK treatment of murine PAM212 keratinocytes stimulated the secretion of RANTES via Fn14 and promoted
apoptosis. Parthenolide, but not wortmanin or the MAPK inhibitor PD98059, signiﬁcantly decreased production
of RANTES, indicating that this effect of TWEAK is mediated via NF-κB signaling. UVB irradiation signiﬁcantly
upregulated the expression of Fn14 on keratinocytes in vitro and in vivo and increased RANTES production. MRL/
lpr Fn14 knockout (KO) lupus mice were compared with MRL/lpr Fn14 wild-type (WT) mice to evaluate for any
possible differences in the severity of cutaneous lesions and the presence of inﬁltrating immune cells. MRL/lpr
Fn14 KO mice had markedly attenuated cutaneous disease as compared with their Fn14 WT littermates, as
evidenced by the well-maintained architecture of the skin and signiﬁcantly decreased skin inﬁltration of T cells
and macrophages. Our data strongly implicate TWEAK/Fn14 signaling in the pathogenesis of the cutaneous
manifestations in the MRL/lpr model of spontaneous lupus and suggest a possible target for therapeutic
intervention.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem auto-
immune disease with a complex and yet to be fully elucidated
etiology (Rahman and Isenberg, 2008; Tsokos, 2011). The
skin is very commonly affected, with approximately 2/3 of
patients developing cutaneous manifestations (Mikita et al.,
2011). In addition, in 25% of patients skin involvement can
appear before the onset of systemic symptoms (Winkelmann
et al., 2013). The morphology of cutaneous lupus can vary
signiﬁcantly, from bullous lesions in an acute form to
atrophic, scarring dyspigmented plaques in the chronic type
(Lin et al., 2007). Of the current approved therapies, none are
approved explicitly for the treatment of cutaneous lupus
(Winkelmann et al., 2013).
Animal models have been instrumental in investigating and
understanding many crucial aspects of human SLE. Several
different mouse strains, both transgenic and spontaneous,
are employed in the study of cutaneous lupus. The most
commonly used model to study lupus skin disease is the MRL/
lpr inbred strain (Ghoreishi and Dutz, 2009). MRL/lpr mice
are homozygous for the lymphoproliferation spontaneous
mutation (Faslpr—tumor necrosis factor (TNF) receptor
superfamily member 6; also known as CD95). Fas has a role
in thymic selection and T-cell survival; the protein is not
found on lymphocytes of MRL/lpr mice, leading to defects in
apoptosis (Drappa et al., 1993). MRL/lpr mice spontaneously
develop disease that very closely mimics human systemic
lupus erythematosus, with multiple organ systems affected.
Both T and B cells aberrantly proliferate, resulting in glome-
rulonephritis, lymphadenopathy, arthritis, and skin disease,
accompanied by high titers of anti-nuclear antibodies and
immune-complex deposition (Cohen and Eisenberg, 1991).
Features of cutaneous disease in MRL/lpr mice include
spontaneous onset of skin lesions similar histopathologically
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to human lupus, overlap in cytokine expression, and
sensitivity to UV irradiation (Menke et al., 2008).
Several members of the TNF/TNF receptor superfamily are
instrumental in the pathogenesis of lupus (Ohl and Tenbrock,
2011), including the TNF, BLyS, and CD40L pathways
(Alaaeddine et al., 2012; Vincent et al., 2012; Zhang et al.,
2012). Another TNF superfamily cytokine more recently
recognized to have a role in SLE is TNF-like weak inducer
of apotosis (TWEAK; Campbell et al., 2006; Winkles, 2008).
TWEAK functions primarily as a soluble cytokine, whose only
known signaling receptor is Fn14, a Type I transmembrane
protein (Wiley and Winkles, 2003). Notably, the expression of
this pathway is increased in settings of tissue injury and
disease (Burkly et al., 2007). Furthermore, TWEAK/Fn14
signaling signiﬁcantly contributes to pathogenesis in murine
models of arthritis, multiple sclerosis, and inﬂammatory
bowel disease. Mechanistic studies have elucidated TWEAK/
Fn14 pathway regulation of multiple disease-driving mechan-
isms, including cell proliferation, cell death, angiogenesis,
inﬂammation and ﬁbrosis, and tissue repair (Zheng and
Burkly, 2008; Burkly et al., 2011).
The role of TWEAK/Fn14 in skin diseases has been scarcely
studied. Fn14 expression is increased in atopic and seborrheic
eczema. However, TWEAK expression was decreased in
these lesions, and circulating TWEAK levels were not elevated
(Chen et al., 2011). Similarly, Peternel found decreased
expression of TWEAK in a variety of inﬂammatory and
neoplastic skin diseases, including psoriasis, lichen planus,
actinic keratosis, basal cell carcinoma, and keratoacanthoma
(Peternel et al., 2011). In contrast, increased TWEAK
was found in human atopic dermatitis lesions (Zimmermann
et al., 2011), whereas Fn14 was elevated in 490% of
melanomas (Zhou et al., 2013). Finally, TWEAK and Fn14
were highly expressed in urticarial vasculitis (Li et al., 2013).
TWEAK may contribute to skin disease via the major
biological processes TWEAK affects, including cell death
and promotion of inﬂammatory cytokines. Thus, we hypo-
thesized that TWEAK is involved in the pathogenesis of
cutaneous disease in SLE, a theory that has not been
previously investigated.
The primary purpose of this study was then to evaluate a
possible role of the TWEAK/Fn14 axis in the development of
skin disease in the MRL/lpr murine model of human
cutaneous lupus. Interestingly, UV exposure is a major trigger
of cutaneous lesions and systemic disease in lupus patients.
Similar to TWEAK/Fn14 signaling, UV irradiation promotes
chemokine secretion and apoptosis (Kuhn et al., 2014).
Therefore, we also explored the possibility that UV irradiation
upregulates the expression of Fn14 and thereby potentiates
the effects of the TWEAK/Fn14 signaling pathway.
RESULTS
PAM212 keratinocytes and WEHI164 ﬁbroblasts express Fn14
To determine whether murine skin cells can be TWEAK
responsive, we assessed for Fn14 receptor expression. Fn14
expression in the murine keratinocyte PAM212 cell line was
comparable to that of mesangial cells, which are known to
express Fn14 (Figure 1a). By ﬂow cytometry, we conﬁrmed
that PAM212 keratinocytes have Fn14 on their cell surface
(Figure 1b). Primary keratinocytes were analyzed as well and
were also found to express Fn14 (Figure 1b). Similarly,
we found that WEHI164 murine dermal ﬁbroblasts express
Fn14 by reverse transcriptase–PCR (RT-PCR; Figure 1a) and
ﬂow cytometry (Figure 1b), consistent with the ability of
human ﬁbroblasts to respond to TWEAK (Chicheportiche
et al., 2002).
TWEAK promotes RANTES production in keratinocytes
Depending on the particular cell type, TWEAK can induce
cytokines including IL-6, IL-8, GM-CSF, monocyte chemotactic
protein-1, and RANTES (Burkly et al., 2007). To determine
which are the inﬂammatory mediators most relevant to the
effects of TWEAK on keratinocytes, we used a multiplex array.
RANTES was one of the most highly expressed cytokines in
this assay; concentrations were approximately 4-fold higher in
supernatants from Fc-TWEAK-treated cells (not shown).
We measured RANTES levels by ELISA in conditioned
medium from PAM212 keratinocytes treated with Fc-
TWEAK and conﬁrmed that Fc-TWEAK induces RANTES
production (Figure 1c). Production of RANTES is at least
partially mediated by NF-κB signaling, as inhibition of this
pathway with parthenolide signiﬁcantly decreased production
of RANTES (Figure 1d). In contrast, the PI3K inhibitor
wortmannin or the MAPK inhibitor PD98059 did not affect
RANTES production (Figure 1d).
TWEAK induces keratinocyte apoptosis
We utilized annexin-V staining to assess keratinocyte
apoptosis induced by TWEAK. We found that ~ 25% of
keratinocytes treated with Fc-TWEAK were annexin-V+; this
level of apoptosis was not seen with untreated or control
treated cells (Figure 1e). Previously, we determined that the
proapoptotic effects of TWEAK are enhanced when used in
combination with IFN-γ (Campbell et al., 2006). Indeed, there
was an increase in annexin-V+ cells following treatment with
a combination of Fc-TWEAK+IFN-γ (Figure 1e). We also
studied TWEAK-induced apoptosis in primary murine kerati-
nocytes and found a similar trend to that observed in PAM212
(not shown).
UVB irradiation upregulates Fn14
Fn14 is consistently expressed at low levels in normal tissues
but is upregulated following a variety of tissue insults (Burkly
et al., 2011). To assess the effect of UVB light on Fn14
expression, PAM212 keratinocytes were exposed to UVB and
the expression of Fn14 measured using RT-PCR and ﬂow
cytometry. RT-PCR revealed an ~8-fold increase in Fn14
expression in UVB-treated cells (Figure 2a). With UVB, and
enhanced with TWEAK co-treatment, increased Fn14 expres-
sion was similarly observed when irradiated cells were
analyzed by ﬂow cytometry, suggesting that the receptor
is prominently upregulated on a cellular subset following
irradiation (Figure 2b). Importantly, upregulation of Fn14
was also seen in vivo, with an increase in dermal Fn14
staining following UVB irradiation of MRL/lpr mice (not
shown).
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UVB in combination with TWEAK increases RANTES and
apoptosis in keratinocytes
As UVB is involved in the pathogenesis of cutaneous lupus
through both proapoptotic and proinﬂammatory effects, we
wanted to assess whether UV enhances the effect of TWEAK
on skin cells. We found that a combination of UVB+Fc-
TWEAK led to a signiﬁcant increase in RANTES production by
PAM212 cells (Figure 2c). Conﬁrming that this heightened
effect observed with UVB+Fc-TWEAK in combination was
not limited to RANTES, we examined the expression of
CSF-1 (a cytokine implicated in cutaneous lupus (Menke
et al., 2008)) and found a similar enhancement following
exposure to both stimuli (not shown). The heightened effect of
UVB+Fc-TWEAK in induction of RANTES was prevented by
an anti-TWEAK antibody (Figure 2d), indicating that the
RANTES-inducing effects of UV on keratinocytes are primarily
mediated by Fn14 upregulation and sensitization of the cells
to the effects of TWEAK, rather than ligand-independent
signaling (Winkles, 2008). Cells treated with UVB+anti-
TWEAK antibody alone, but without TWEAK, did not produce
RANTES (not shown). Furthermore, we found that keratino-
cytes treated with UVB+Fc-TWEAK showed a signiﬁcantly
increased apoptotic response (Figure 3a and b). A similar
result was found when comparing UVB+Fc-TWEAK versus
UVB alone (Figure 3a and b). Taken together, these results
point to a shared effect of UVB and TWEAK that can drive the
production of RANTES and promote keratinocyte apoptosis.
MRL/lpr mice lacking Fn14 have attenuated cutaneous disease
MRL/lpr mice spontaneously develop severe cutaneous
lesions that share multiple features with human chronic
cutaneous lupus, including erythematous, hyperkeratotic, and
often eroded plaques macroscopically, and interface derma-
titis with peri-adnexal lymphocytic inﬁltrate and follicular
plugging microscopically (Furukawa et al., 1996). To evaluate
the role of TWEAK/Fn14 in the pathogenesis of cutaneous
lupus, we generated and studied Fn14 knockout (KO) mice on
the MRL/lpr background. MRL/lpr Fn14 wild-type (WT) and
MRL/lpr Fn14 KO mice were scored blindly to assess the
severity of skin disease. Male and female mice were initially
scored separately; as the differences in skin scores at this age
were not signiﬁcant, mice from both genders were combined.
MRL/lpr Fn14 KO mice had signiﬁcantly attenuated skin
disease as compared with MRL/lpr Fn14 WT mice (Figure 4a).
When analyzed histologically, we found that MRL/lpr Fn14
WT mice showed characteristic cutaneous lupus lesions,
including an acanthotic epidermis, follicular plugging, inter-
face dermatitis, and, in some cases, a lobular panniculitis with
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Figure 1. Fn14 expression and RANTES production in skin cells. (a) RT-PCR for Fn14 expression, with fold change calculated versus an irrelevant hybridoma set
at 1. (b) Fn14 expression by ﬂow cytometry (red, unstained; blue, control; orange, Fn14). (c) PAM212 keratinocytes were untreated or incubated with TWEAK or
control Ig (0.1 μgml−1) for 48 hours. (d) PAM212 keratinocytes were pretreated with wortmanin, parthenolide, or PD98059, followed by Fc-TWEAK or control Ig
for 48 hours. (e) PAM212 keratinocytes were treated for 48 hours (1 μgml−1 Fc-TWEAK, 1 μgml−1 control Ig, 1 μgml−1 Fc-TWEAK+80 IUml−1 IFN-γ, and
1 μgml−1 control Ig+80 IUml−1 IFN-γ) and stained with annexin-V and 7-AAD. The ﬁgure shows the number of early apoptotic keratinocytes with each
treatment. The ﬁgures shown are representative of two or three independent experiments. **Po0.01, ***Po0.001, and ****Po0.0001. RT-PCR, reverse
transcriptase–PCR; TWEAK, Tumor necrosis factor-like weak inducer of apoptosis.
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evidence of hyalanizing necrosis (Figure 4b). In contrast,
MRL/lpr Fn14 KO mice showed relatively normal skin
architecture, with no thickening of the epidermis or involve-
ment of the dermo-epidermal junction (Figure 4b). Detailed
macroscopic scoring revealed that MRL/lpr Fn14 WT mice
had more erythema, thickness, and scaling of the skin as
compared with MRL/lpr Fn14 KO mice, particularly in both
the trunk (Figure 4c) and head regions. No signiﬁcant
difference in the scores for alopecia was seen between the
MRL/lpr Fn14 WT (0.75±0.16) and the MRL/lpr Fn14 KO
(0.5±0.28) strains (P= 0.43).
Immunohistochemistry conﬁrmed more active inﬂamma-
tion in the skin of MRL/lpr Fn14 WT mice, with greater
inﬁltration of CD3+ T cells concentrated perifollicularly, as
well as IBA-1+ macrophages (Figure 5a and b). In contrast,
MRL/lpr Fn14 KO mice had very few inﬁltrating cells, none of
which were concentrated in particular areas of the skin. The
skin from MRL/lpr Fn14 WT but not KO mice stained positive
in a TUNEL assay, indicating that cell death by apoptosis is
more prominent in the skin of Fn14 WT lupus mice
(Figure 5c).
Finally, to determine the possible relevance of the TWEAK/
Fn14 pathway to human disease, in a preliminary study, we
stained skin biopsies from lupus patients for Fn14. As seen in
Figure 6, three of three lesional lupus skin biopsies demon-
strated prominent Fn14 staining, particularly in the dermis.
Interestingly, in some biopsies of non-lesional skin, epidermal
Fn14 staining was present as well (Figure 6).
DISCUSSION
We found that TWEAK signaling via Fn14 has an important
role in the pathogenesis of skin disease in the MRL/lpr lupus
strain. Our studies conﬁrm the presence of the Fn14 receptor
on both transformed and primary murine keratinocytes and
demonstrate that TWEAK induces apoptosis and RANTES
production. Adding UVB further increases the levels of Fn14
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Figure 2. Effects of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and UV. (a) PAM212 keratinocytes were UV irradiated for 30 seconds and/or
treated with TWEAK and Fn14 measured by PCR. (b) PAM212 keratinocytes were treated as speciﬁed and analyzed for Fn14 receptor expression by ﬂow
cytometry. Cells were gated in two populations, and Fn14+ cells from P1 and P2 of each group were compared. (c) Cells were UVB irradiated for 10 or 15
seconds as indicated and treated with 1 μgml−1 Fc-TWEAK or control Ig. (d) Cells were treated with Fc-TWEAK or control Ig (0.1 μgml− 1) or UVB irradiated.
Irradiated cells were also treated with TWEAK pre-incubated or not with an anti-TWEAK mAb. In panels (c) and (d), supernatants at 48 hours were analyzed by
ELISA. The ﬁgures shown are representative of at least two or three independent experiments. *Po0.05, **Po0.01, ***Po0.001, and ****Po0.0001.
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expression, keratinocyte apoptosis, and RANTES when
compared with TWEAK or UVB alone. Interestingly, not all
keratinocytes upregulated Fn14 with UVB, perhaps due to
cell-cycle-related differences in sensitivity to irradiation.
In vivo, MRL/lpr Fn14 KO mice have signiﬁcantly attenuated
skin disease and markedly fewer skin inﬁltrating macrophages
and T cells. This protection is likely to be mediated by
abrogated TWEAK/Fn14-mediated stimulation of keratinocyte
RANTES production and apoptosis.
Several studies have demonstrated the involvement of
TWEAK in the pathogenesis of autoimmune disease models,
including arthritis, EAE, and colitis (Desplat-Jégo et al., 2005;
Kamata et al., 2006). More recent studies have shown that the
TWEAK/Fn14 axis contributes to end organ pathology in
systemic lupus; TWEAK/Fn14 pathway inhibition attenuated
lupus-associated nephritis (Michaelson et al., 2012; Xia et al.,
2014) and neuropsychiatric disease (Wen et al., 2013).
Our current report is unique in that it supports a previously
unrecognized involvement of TWEAK/Fn14, possibly in
conjunction with UVB irradiation, in the pathogenesis of
cutaneous lupus manifestations.
The detrimental effects of UV on keratinocytes are
comparable in mice and humans. In vitro, keratinocytes from
MRL/lpr mice and humans are susceptible to UV toxicity (Lin
et al., 2007). In the MRL/lpr strain in vivo, UVB activates and
recruits macrophages, which then can release mediators that
induce keratinocyte apoptosis and exacerbate skin disease
(Menke et al., 2008). Similarly, UV is a well-known trigger for
skin disease in human lupus patients. The skin is routinely
exposed to UVA and UVB, both of which can elicit the
formation of cyclobutane pyrimidine dimers and reactive
oxygen species, which can damage DNA. Importantly,
keratinocytes in particular are often the main target of UV-
induced inﬂammation, DNA damage, and apoptosis because
of their superﬁcial localization within the epidermis (Matsuda
et al., 2010). UV can induce apoptosis and necrosis, which
can initiate immune responses through the uptake of
apoptotic blebs by dendritic cells (Furukawa, 2003; Schulze
et al., 2008). Defective clearance and/or an excess supply of
apoptotic debris can provide an abundant supply of lupus-
related autoantigens, thus promoting the generation of
autoantibodies and leading to immune-complex formation,
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deposition at the dermal–epidermal junction, and comple-
ment activation (Oke and Wahren-Herlenius, 2013).
TWEAK induces the production of RANTES, a T-cell
chemoattractant important in the pathogenesis of psoriasis
(Fukuoka et al., 1998) and atopic dermatitis (Kaburagi et al.,
2001). Interestingly, Van Nguyen recently showed intense
RANTES staining in the skin of lupus patients with cutaneous
involvement, particularly epidermal keratinocytes (Van
Nguyen et al., 2011). UV irradiation can lead to increased
production of chemokines/cytokines by keratinocytes and
other cell types in the skin, which also promotes local
inﬂammation (Lee et al., 2013). Regarding the production of
RANTES by human keratinocytes induced by UV irradiation,
studies have been conﬂicting. Arakawa found that UVB
irradiation alone of human epidermal keratinocytes could not
induce the production of RANTES; only when cells were
treated with TNF or IFN-γ following irradiation did production
of RANTES become evident (Arakawa et al., 2006). In
contrast, Van Nguyen reported RANTES induction by UVB
in a time- and a dose-dependent manner (Van Nguyen et al.,
2011).
Our results are consistent with previous studies showing
that human keratinocyte–derived cells, HaCaT, have
increased apoptosis after TWEAK exposure. This same study
also looked at Fn14+ primary cells from patients with atopic
dermatitis and psoriasis; these cells did not undergo apoptosis
when treated with TWEAK alone but became more sensitive
to the apoptotic effect of TWEAK when pre-treated with
cycloheximide or in combination with TNF (Zimmermann
et al., 2011). Similarly, Fn14+ human foreskin keratinocytes
showed a dose-dependent apoptotic response to TWEAK
(Sabour Alaoui et al., 2012).
We clearly demonstrate here apoptosis and production of
RANTES following TWEAK treatment of murine keratinocytes,
which had not been previously described (Jin et al., 2004).
This is an important ﬁnding, as it is of direct relevance to the
pathogenesis of cutaneous disease in MRL/lpr mice.
Interestingly, TWEAK signaling can proceed via multiple
intracellular signaling pathways including NF-κB, MAPK (via
ERK, JNK, or p38), and PI3K/AKT (Winkles, 2008; Burkly
et al., 2011). Our studies showed that RANTES production
was only blocked by parthenolide, but not inhibitors of MAPK
or PI3K, indicating that NF-κB signaling is the pathway
relevant for RANTES production via Fn14 in keratinocytes.
Another unique observation was that exposure to UVB
+TWEAK leads to a synergistic increase in RANTES, likely
through sensitization of the keratinocytes to the inﬂammatory
effects of TWEAK mediated by the increased expression of
Fn14 following UVB.
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MRL/lpr Fn14 KO, n= 15). Right panels show representative photographs of macroscopic skin lesions in MRL/lpr Fn14 WT (34 weeks) and MRL/lpr Fn14 KO mice
(42 weeks). The left and right panels in each row of photographs depict the same mouse, before and after hair removal with Nair cream to better demonstrate the
skin lesions. (b) Representative images of H&E stained sections from MRL/lpr Fn14 WT and MRL/lpr Fn14 KO mice (scale bar = 7mm). Asterisk indicates
hypergranulosis. Arrowhead indicates parakeratosis. Arrow points toward an area of acanthotic epidermis. (c) Fn14 WT mice had signiﬁcantly higher scores in the
trunk region. **Po0.01 and ***Po0.001. H&E, hematoxylin and eosin; WT, wild type.
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Our ﬁndings in this study strongly suggest a previously
unrecognized pathway in the pathogenesis of chronic
cutaneous lupus erythematosus. We propose a model in
which TWEAK stimulation of keratinocytes leads to the
production of RANTES, a known chemotactic protein for
T cells and other inﬂammatory cells. Exposure to UVB in
addition to TWEAK may further exacerbate the production of
RANTES (and perhaps other cytokines as well), creating an
inﬂammatory local environment and further attracting inﬁl-
trating cells. TWEAK, as does UV irradiation, also leads to
apoptosis of keratinocytes, which can further contribute to the
development of the cutaneous lesions.
The pathogenesis of inﬂammatory skin disease in SLE is
admittedly complex and most likely involves multiple cyto-
kines and several cellular pathways, not all of which are
directly related to, or inﬂuenced by, TWEAK/Fn14 interactions.
Nevertheless, the protection of MRL/lpr Fn14 KOmice from the
macroscopic and microscopic manifestations of lupus-like skin
disease in this model is highly signiﬁcant and suggests that
blockade of even a single cytokine may be beneﬁcial for this
particular disease manifestation. Furthermore, Fn14 upregula-
tion was present in human lupus skin. It remains to be
determined in future studies how TWEAK combines with other
central pathogenic pathways, such as UVB, in triggering
cutaneous inﬂammation in the intact animal as well.
In summary, we have demonstrated that TWEAK and UVB,
alone and in combination, lead to inﬂammation and apop-
tosis in murine keratinocytes. Furthermore, MRL/lpr Fn14 KO
mice have signiﬁcantly attenuated cutaneous disease with
reduced inﬁltration of T cells and macrophages. The results
from the in vitro studies and in vivo correlative studies
suggest that Fn14 deﬁciency is protective due to reduced
RANTES and keratinocyte apoptosis. We propose that the
TWEAK/Fn14 axis contributes to the pathogenesis of cuta-
neous lupus and that this signaling pathway represents a
potential therapeutic target for biological agents.
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Figure 5. MRL/lpr Fn14 knockout (KO) have fewer skin inﬁltrating cells and less epidermal apoptosis. (a) Representative images of CD3 stained sections from
randomly selected MRL/lpr Fn14 WT (n=7) and Fn14 KO (n=5) mice (39 weeks; scale bar = 7mm). Cell counts are in the right panel. (b) Representative images
of IBA-1 stained sections from randomly selected MRL/lpr Fn14 WT (n= 4) and MRL/lpr Fn14 KO (n=8) mice (scale bar = 7mm). Images were analyzed for
staining density using ImageJ (NIH, Bethesda, MD). (c) Lesional and unaffected skin was taken from randomly selected MRL/lpr Fn14 WT (n= 6) and MRL/lpr
Fn14 KO (n=6) mice. The TUNEL assay was performed on parafﬁn-embedded skin sections. Shown here is a representative image from 1 mouse in each group
(scale bar = 14mm). Fluorescence intensity was measured using ImageJ (right panel). *Po0.05 and ***Po0.001. WT, wild type.
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MATERIALS AND METHODS
Cells and reagents
PAM212, a BALB/c-derived keratinocyte cell line (Tron et al., 1990),
and WEHI164, a skin ﬁbroblast cell line established from a BALB/c-
derived ﬁbrosarcoma, were grown in 10% DMEM and maintained at
37 °C per 5% CO2. Isolation and culture of primary keratinocytes
were performed essentially as described (Jensen et al., 2013). For
stimulation assays, cells were incubated with murine Fc-TWEAK (Wu
et al., 2013) or an IgG2a isotype control P1.17 (ATCC, Manassas,
VA).
RNA isolation and RT-PCR
RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA),
and reverse transcription was performed using the Superscript First-
Strand System (Life Technologies, Norwalk, CT). Real-time PCR was
performed in triplicate by the SYBR green method (Life Technologies,
Norwalk, CT). The gene of interest was normalized to the average of
two housekeeping genes (GAPDH and tubulin), and fold changes
were determined using the ΔΔCT method.
Flow cytometry for detection of cell surface Fn14 expression
PAM212 keratinocytes and WEHI164 ﬁbroblasts were detached with
0.25% Trypsin-EDTA, then washed, and resuspended in FACS buffer.
A total of 2.5× 105 cells were incubated with an Fn14-speciﬁc Fab’2
(derived from P4A8; Michaelson et al., 2011) or a control Fab’2
MOPC-21 for 30 minutes. Cells were washed three times, and ﬂow
cytometry performed on a FACSCalibur instrument (BD Biosciences,
San Jose, CA). Primary keratinocytes were similarly detached and
incubated with 0.5 μgml− 1 Fc-block for 5 minutes at 4 °C. ITEM-4
(Santa Cruz Biotechnology, Dallas, TX) or control murine IgG2b was
added for 60 minutes at 4 °C. Next, the cells were washed in FACS
buffer and incubated with biotinylated goat anti-mouse IgG2b for
30 minutes at 4 °C followed by allophycocyanin-streptavidin for
30 minutes at 4 °C.
Apoptosis
Keratinocytes (3× 104) were allowed to adhere overnight at 37 °C per
5% CO2. Fc-TWEAK, control Ig, or Fc-TWEAK+IFN-γ were added to
each well for 48 hours. Following treatment, cells were harvested
and resuspended in annexin binding buffer in 2% fetal bovine serum.
Annexin-FITC was added to each sample and incubated for
15 minutes on ice. 7-AAD was then added, and samples were
immediately processed on a FACSCalibur or LSRII instrument. In this
assay, early apoptotic cells are annexin+ and 7-AAD− , whereas late
apoptotic cells stain positive both for annexin and 7-AAD.
Cytokine array
PAM212 cells were treated with Fc-TWEAK or control Ig for 48 hours.
Supernatants were collected and incubated with pre-coated membranes
for cytokine detection (AAM-CYT-1) (RayBiotech, Norcross, GA).
RANTES ELISA
PAM212 cells (5× 104) were seeded in multiwell plates and allowed
to adhere overnight. The following day media were removed, and the
cells were washed and treated with Fc-TWEAK, control Ig, IFN-γ, Fc-
TWEAK+IFN-γ, or control Ig+IFN-γ. Supernatants were analyzed
using a RANTES ELISA Kit (R&D Systems, Minneapolis, MN).
UVB irradiation
PAM212 cells were exposed to UVB light using a 302 nm UVM-57
lamp (UVP, Upland, CA) and either left in media alone or treated
with Fc-TWEAK or control Ig for 48 hours. RANTES concentrations
were measured by ELISA, or the cells were harvested and analyzed
for apoptosis as described above. For quantiﬁcation of gene
expression, cells were harvested after 24 hours, and RNA was
isolated for RT-PCR.
Cell signaling
PAM212 cells (5× 104) were washed with phosphate-buffered saline
(PBS) and pre-treated for 2 hours with 10 μM parthenolide (Santa Cruz
Unstained Normal Normal
SLE, non-lesionalSLE, lesionalSLE, lesional
100 µm 100 µm 100 µm
100 µm200 µm500 µm
Figure 6. Human lupus skin biopsies stain positive for Fn14. Parafﬁn tissue sections were stained for Fn14 by immunohistochemistry, as described in the Materials
and Methods. The top left panel shows the negative control (primary antibody withheld, normal skin; scale bar = 14mm). The top middle and right panels show
stained normal skin, displaying minimal Fn14 positivity (scale bar = 14mm). The bottom left (scale bar = 9mm) and middle panels (scale bar = 14mm) show two
magniﬁcations of a stained section from a lupus discoid skin lesion. There is marked dermal Fn14 staining, which is representative of the pattern seen in two
additional lupus discoid skin lesion biopsies. The bottom right panel shows Fn14 staining in a non-lesional lupus skin biopsy (scale bar = 14mm).
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Biotechnology), wortmannin (Tocris Biosciences, Minneapolis, MN),
or PD98059 (Cell Signaling, Beverly, MA), followed by Fc-TWEAK
or control Ig for 48 hours. Supernatants were analyzed by
RANTES ELISA.
Animals
MRL/lpr Fn14 KO (ninth generation) and WT littermates were
maintained at Einstein (Jakubowski et al., 2005). MRL/MpJ mice
were from Jackson Laboratories (Bar Harbor, ME). All animal study
protocols were approved by the Institutional Animal Care and Use
Committee of the Albert Einstein College of Medicine.
Scoring of skin lesions
Mice were scored blindly by trained observers every 2 weeks from 26
to 54 weeks of age, and an average score recorded for each mouse.
Plaque characteristics in multiple body regions were given numerical
scores and were further adjusted for the extent of involvement and
body surface area covered (Supplementary Figure S1 online). The
scoring system was designed combining features of the psoriasis area
and severity index and the cutaneous lupus area and severity index
scoring systems, with the maximum score being 72 (Albrecht et al.,
2005; Feldman and Krueger, 2005).
Histopathology and immunohistochemistry
Tissue samples were immersed in 10% buffered formalin for
48 hours at 4 °C. Samples were then transferred to 70% ethanol
and parafﬁn embedded and stained using hematoxylin and eosin.
For immunohistochemical staining, reagents included antibodies to
CD3, IBA-1, and Fn14. Following the addition of substrate solution,
slides were rinsed in ddH20, stained in Mayer’s hematoxylin,
washed, air-dried, and mounted with Permount (Fisher,
Pittsburgh, PA).
Human skin biopsies were obtained following written informed
consent, with the protocol approved by the IRBs at NYU and the
Albert Einstein College of Medicine. For parafﬁn slide staining, heat-
induced antigen retrieval was performed using a pH 6.0 citrate buffer
for 10 minutes. After cooling, slides were washed in PBS and
subsequently blocked in dual endogenous enzyme block for
10 minutes. Following two washes in PBS-Tween, slides were
incubated with a rabbit anti-human antibody to Fn14 (Cell Signaling,
Beverly, MA) at a dilution of 1:100 in 1% PBS/bovine serum albumin
overnight at 4 °C. Slides were washed in PBS-Tween and incubated
with biotinylated anti-rabbit secondary antibody (2 hours at room
temperature) followed by streptavidin-horseradish peroxidase
(30 minutes at room temperature). Color was developed using 3,3′-
diaminobenzidine substrate, and slides were counterstained using
hematoxylin.
Analysis
The results shown are mean+SE. Values of Po0.05 were considered
signiﬁcant.
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